Study finds Herceptin use can be halved

09:40 EDT 17 May 2018 | Pharmafile

A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just as effective after a reduced treatment period of six months compared with the standard 12 months, in women with HER2 positive early-stage breast cancer.

This is a significant finding for a few reasons: the main one being that patients could receive less courses of treatment, which was found to be associated with reduced levels of side-effects.

Image caption: 
IMAGE: Tiffany Trojca

read more

Original Article: Study finds Herceptin use can be halved


More From BioPortfolio on "Study finds Herceptin use can be halved"

Quick Search


Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...